Glucocorticoid (GC) remain the cornerstone of remission induction in GCA, exerting their anti-inflammatory effects through downregulation of pro-inflammatory genes, upregulation of GC receptor targets (e.g., FKBP5), and increased expression of anti-inflammatory markers such as CD163 [91,92]. The gene discussed is FKBP5; the disease is temporal arteritis.